INOVIO’s COVID-19 DNA vaccine INO-4800 provided protection with memory immune responses In non-human primates challenged with SARS-CoV-2 virus
On Jul. 30, 2020, INOVIO announced that its COVID-19 DNA vaccine INO-4800 targeting SARS-CoV-2 was effective in protecting non-human primates (NHPs; specifically rhesus macaques) from live virus challenge 13 weeks after the last vaccination.
These protective results were mediated by memory T and B cell immune responses from INO-4800 vaccination.
Tags:
Source: Inovio Pharmaceuticals
Credit:
